Positive Preclinical Results Unveiled for DPH001

We’re delighted to share positive results from our recent preclinical study for DPH001. With our innovative MMC technology, researchers at Disruptive Pharma have engineered an improved sorafenib formulation intended for the treatment of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). DPH001, confirms its bioequivalent exposure profile at 50% API dose compared to NEXAVAR^® Our data show that the MMC sorafenib formulation of DPH001 achieved the 2X absorption and reduced inter-animal variability which was the goal of the PK study. The animals were given MMC sorafenib formulation, at 50% API dose, and NEXAVAR^®at standard API dose. CEO Peter Åsberg: “we look forward to continue developing DPH001 which will bring an important improvement for patients with HCC/RCC. We believe it can have a major impact on the market and have a positive impact for the patients in terms of an improved side-effect profile undergoing sorafenib treatment. We’re really excited about our upcoming work and the commercial opportunities we see that DPH001 can bring as well as being a demonstrator on how the patented MMC technology may be utilized to create improved versions of marketed products.”

Furthermore, Åsberg highlighted the broader potential of Disruptive Pharma’s MMC technology, which could pave the way for enhanced versions of existing products, stating, “DPH001 serves as a prime example of how our patented MMC technology can be harnessed to create superior iterations of marketed products. This not only demonstrates our commitment to innovation but also underscores our dedication to improving patients’ lives.”